Dogwood Therapeutics announces $5 million private placement with CK Life Sciences
DWTX•Dogwood Therapeutics agreed to a $5 million private placement with a subsidiary of its largest shareholder, selling 4,098,360 shares at $1.22 each. The proceeds are expected to extend its operational runway through March 2027.
1. Private placement details
Dogwood Therapeutics agreed to sell 4,098,360 shares of common stock at $1.22 per share to a subsidiary of CK Life Sciences in a $5 million private placement. The transaction is expected to close by October 29, 2026, and includes no warrants or other derivative securities.
2. Use of proceeds
The company plans to use the proceeds for Halneuron Phase 3 preparations and general corporate needs, extending its operational runway through March 2027. Topline data from the Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain are expected in November 2026.
